SBA loans for medical laboratories

What the approvals say about lab borrowers

Medical laboratories (NAICS 621511) took 119 SBA 7(a) loans from FY2024 through June 2026, worth $56,485,200, from 47 different lenders. That is a broad lender base for a small industry. Labs are not a specialist's niche the way farms are: a lender comfortable with physician practices will usually read a lab file.

The loans are modest. The median was $200,000, the middle half ran from $75,000 to $426,250, and the 90th percentile was $848,140. Only 10 loans, 8.4% of the total, reached $1 million. A median of six jobs per loan fits the picture: most borrowers are independent clinical and reference labs, toxicology and drug-testing labs, and specialty labs, not regional networks. The money goes to analyzers, build-outs, working capital to carry payer receivables, and buying out a partner or a competitor.

Why lab rates sit next to the national median

SBA caps variable 7(a) rates by loan size: the base rate plus 6.5% at $50,000 or less, plus 6% from $50,001 to $250,000, plus 4.5% from $250,001 to $350,000, and plus 3% above $350,000. The median lab loan and the national median both fall in the band from $50,001 to $250,000, and the two median rates land a quarter point apart. The spread inside the industry is wider than that gap: the middle half of lab loans priced from 9.5% to 11.25%, and most of the difference is loan size and program.

SBA Express was 32.8% of lab loans. Express goes up to $500,000 with a 50% guaranty, against 85% on a standard 7(a) of $150,000 or less and 75% above that, and lenders price the thinner guaranty. A lab borrowing for one analyzer or a small build-out often takes Express for the lighter paperwork; a lab borrowing for an acquisition or a larger expansion usually belongs in a standard 7(a). See SBA 7(a) vs SBA Express, SBA maximum interest rates and current SBA loan rates.

Only 14.3% of lab loans were fixed-rate. With a median term of 120 months, most lab borrowers finance equipment and working capital over ten years, and a variable rate on a ten-year loan is a smaller risk than on a 25-year mortgage. See fixed vs variable rate.

Payers are the credit

A lab rarely chooses its price. Medicare's clinical laboratory fee schedule, state Medicaid programs and commercial payer contracts set what each test earns, and payers revise those rates, narrow coverage and deny claims on documentation. A lender therefore reads a lab's revenue by who pays it and how reliably, not by the total on the P&L.

Two patterns get extra attention. The first is revenue from a testing program that has run its course. A lab that grew on a surge of one test type, a public-health contract or a single employer's screening program will be underwritten on what remains once that revenue is taken out. SBA requires debt service coverage of at least 1.15x, and 1.0x globally once the owners' own income and debts are counted, and a lender runs that test on earnings it believes will repeat. See debt service coverage and global cash flow.

The second is referral relationships. Lenders ask who sends the work, whether any referring physician owns part of the lab, and how the lab pays its sales staff or marketers, because a compliance problem with a payer can stop revenue faster than any market change. A lab that concentrates its volume in a few clients should expect the questions on customer concentration as well.

A lab's earnings are only as good as the claims that get paid: lenders underwrite collections, not billings.

Collateral a lender can count

Labs are light on hard collateral. Analyzers are often leased or placed by the vendor in exchange for a reagent purchase commitment, so the lab does not own them. Owned equipment is specialized, with a thin resale market, and an appraiser values it on liquidation, not on cost. Payer receivables are real but carry denials and slow pay. Every owner of 20% or more personally guarantees an SBA loan, and where business assets fall short, SBA lenders often take a lien on the owners' personal real estate where it has meaningful equity. See equipment appraisals and the personal residence as SBA collateral.

Thin collateral is not a decline in itself. SBA lends on cash flow, and a lab with steady collections spread across payers is financeable without full collateral coverage; it means the cash-flow analysis carries the file. For a lab whose growth is outrunning its collections, a line of credit against payer receivables can sit beside the term loan. See lines of credit for medical practices.

A lab that has carried its receivables with merchant cash advances has a narrower path. SBA will not refinance an active advance, and from 1 October 2026 an advance becomes eligible only once it has been converted to a term loan that has amortized for at least 24 months with no new advance since. See refinancing cash advances for healthcare providers.

The 13 SBA 504 loans, median $832,000, are labs buying or building their own space. A 504 borrower must occupy at least 51% of an existing building, or 60% of new construction, and the usual split is 50% from a bank, 40% from the CDC and 10% from the borrower, rising to 15% for a new business or special-purpose property. Laboratory ventilation, plumbing and power specific to the work can push a building toward special-purpose treatment. See SBA 7(a) vs 504.

Start-ups and franchised testing sites

Start-ups were 21.8% of lab loans. SBA requires an equity injection of at least 10% of total project costs for a start-up, and a lender will want the pieces that let a new lab bill either in place or firmly scheduled: the CLIA certificate, state licenses, a qualified laboratory director, payer enrollment, and letters or contracts from the clients who will send work. The owner's experience weighs more than usual; SBA's Form 1919 asks about it, and a lender reads the resume against the tests the lab plans to run.

Franchises were 16.8% of loans, a high share for a clinical industry. A likely source is consumer testing brands, drug, DNA and paternity testing sites that collect specimens and send them to a reference lab, which can sit in this code beside clinical labs. Those are small loans on a brand's system: the lender reads the franchise agreement, the franchisor's support and local demand rather than payer contracts.

Buying a lab

Acquisitions were 11 loans, 9.2% of the total, close to the national 10.4%, at a median of $440,000 and 10.25%. Buying a lab is buying its certifications, payer enrollments and referral base, and each has to survive the change of ownership.

• Structure matters. In an asset purchase the buyer may need new or reassigned payer enrollments, and payments can pause while they are processed; in a stock purchase the enrollments stay, and so do the entity's liabilities, including any payer audit. Lenders size working capital at close for the gap. See asset vs stock purchase and working capital at close.
• At least 10% of total project costs as equity. A seller note counts toward half of it only if it is on full standby, no principal or interest, for the life of the SBA loan. See seller notes and SBA standby.
• Where the amount financed, less appraised real estate and equipment, exceeds $250,000, SBA requires an independent business valuation, and the loan cannot exceed it. Much of a lab's price is goodwill, so many lab purchases cross that line. See the SBA valuation requirement.
• The seller cannot stay as an owner, officer or employee but may consult for up to 12 months, or up to 24 months under SOP 50 10 8.1 from 1 October 2026. If the seller is also the laboratory director, the buyer needs a qualified director named before closing.
• From 1 October 2026 a change of ownership must show 1.25x debt service coverage on historical results, and financial due diligence is required on every one. A buyer should know in advance how the lender will treat any year distorted by a one-time testing program.

More on buying a practice with payer revenue is in financing a medical practice acquisition.

Preparing a lab's file

The SBA list: 2–3 years of business tax returns, a P&L and balance sheet with a year-to-date P&L through last month-end, a debt schedule with copies of any notes being refinanced, and personal tax returns and a personal financial statement for each owner of 20% or more, with the owner's resume.

Then what a lab lender asks for next: payer mix and collections by payer for each year, AR aging by payer, test volumes by month, the CLIA certificate, state licenses and accreditation, the laboratory director's credentials, equipment leases and reagent agreements, and any payer audit or recoupment letters. Transparent builds that into a full lender package — financing model, lender presentation, blind teaser and underwriting memo — in a day once the documents are in, and takes it to the lenders among the 278 in its book that write SBA 7(a) and 504. On SBA loans the lender pays Transparent, not the borrower. See the package and how we underwrite.